# Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention

Study · id `cardio:ct-nct04778787` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04778787](<https://clinicaltrials.gov/study/NCT04778787>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04778787

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 370 participants.

## Technical summary

Registry record NCT04778787. Randomized; single masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2022-08-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 370 participants (enrolled count; ClinicalTrials.gov record NCT04778787, source copy `cardio:ctgov-nct04778787-2022-12-07`, retrieved 2026-10-26)
- Started: 2021-01-01 (actual) (ClinicalTrials.gov record NCT04778787, source copy `cardio:ctgov-nct04778787-2022-12-07`, retrieved 2026-10-26)
- Primary completion: 2022-08-01 (actual) (ClinicalTrials.gov record NCT04778787, source copy `cardio:ctgov-nct04778787-2022-12-07`, retrieved 2026-10-26)
- Completion: 2022-08-01 (actual) (ClinicalTrials.gov record NCT04778787, source copy `cardio:ctgov-nct04778787-2022-12-07`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT04778787, source copy `cardio:ctgov-nct04778787-2022-12-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04778787-2022-12-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention
- Condition: Congestive Heart Failure
- Intervention (Drug): Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
- Lead sponsor: I.M. Sechenov First Moscow State Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: I.M. Sechenov First Moscow State Medical University (`cardio:org-i-m-sechenov-first-moscow-state-medical-university`)

## Provenance

Content hash: 1329ac14371aa2ae308c5596caa0b75a8615258d3418c2066a2b8b515468ebe5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
